Drugs for Bugs: The Next Generation of Pharmaceuticals

Size: px
Start display at page:

Download "Drugs for Bugs: The Next Generation of Pharmaceuticals"

Transcription

1

2 Drugs for Bugs: The Next Generation of Pharmaceuticals Mark Pimentel, MD, FRCP(C) Executive Director, Medically Associated Science and Technology (MAST) Program Cedars-Sinai Medical Center

3 Microbiome The microbiome can t cause everything Patients

4 How to Treat the Microbiome? Antibiotics Kill or inhibit bacteria Probiotics Replace a deficiency of one or more bacteria Take advantage of a benefit provided by certain bacteria Fecal microbial transplant (FMT) Who is normal? Genetically engineered bacteria Produce a product that can treat human disease or promote health Drugs for bugs Not meant to kill but rather affect the production pathways of bacteria

5 Bugs as Drugs A. Probiotics - Finding bacteria that naturally produce something that is beneficial (e.g. anti-inflammatory) - Finding bacteria or sets of bacteria that restore balance Pros Simple Promising basic science Cons No magic bullets yet FDA hurdles Too many products

6 What Probiotic Should I Use? 64 different probiotics listed Refridgerated/dessicated $

7 Some of the Benefits Bifidobacter Reduces TNF Enhances mucosal IL-10 (anti-inflam) Diminishes LPS Affects toll receptors Inhibits pathogenic bacteria Improves epithelial tight junctions Promotes MMC s Increased acetate production Inhibits biofilm production Increases CD4+ T cells Decrease CD4+/CD8+ cells Many other effects

8 Bugs as Drugs B. Fecal Transplant -Replacing the whole gut microbiome Pros Simple Very promising (e.g. C diff) Cons Complications FDA hurdles What is normal feces?

9 SER-109 Not FMT but a cocktail of spores isolated from normal human stool To establish normal flora in the treatment of recurrent C. difficile infection Then 2016 happened

10 Bugs as Drugs C. Genetically modified bacteria -Contains desired gene (eg anti-tnf biologic) -Also needs kill switch Pros Simple Very promising (e.g. C diff) -Incorporates in gut microbiome to produce product (absorbed or local) Cons Complications FDA hurdles What is normal feces?

11 Kill Switches 1. Deficiency Switch Probiotic Beneficial Product/effect AA Engineered such that cannot produce an essential amino acid

12 Kill Switches 2. Deadman Switch Probiotic Toxin Beneficial Product/effect Inhibitor Blocks the production of toxin

13 Kill Switches 3. Passcode Switch Probiotic Toxin Beneficial Product/effect Multiple agents Very complex because its like a combination lock All the agents need to be there or the bacteria dies Benefit: Hard to imagine the environment might figure it out and all the bacterium escape

14 Elafin Producing Bacteria ViThera Pharmaceuticals developing VT301 for Crohn s disease Engineered Lactococcus lactis and lactobacillus caseii to produce elafin Elafin is a protease inhibitor that is produced by normal human epithelium and deactivates elastase and proteinase-3 In IBD elafin is reduced and this could allow elastase and proteinase to damage the gut wall Success in animal models Motta JP, et al. Sci Transl Medicine, 2012

15 Bacterial Injection Injecting solid tumor with bacteria Strong quorum sensing Bacteria are microaerophilic so die when in oxygen so stay in blood starved tumor Bacteria draws inflammation and kill of tumor cells Zheng, et al. Sci Translat Med, 2017

16 Protecting Good Bugs iv antibiotics Gut penetration Beta lactamase SYN-004 Pros Simple Proven effective Cons B-lactams only

17 Why is Rifaximin a Microbiome Drug? 1. Not systemic 2. Soluble in bile in small bowel, precipitates in the colon 3. Works only in the small bowel 4. No yeast accumulation 5. 98% of stool flora unchanged after 3 courses of rifaximin 6. No development of bacterial resistance Kim, et al. Dig Dis Sci 2013 Pimentel, et al. Dig Dis Sci 2017

18 TARGET 1 and 2 Trials for IBS Primary Primary Efficacy Outcome Efficacy Outcome SGA-IBS Weekly SGA-IBS Weekly Study TARGET Study TARGET 1 TARGET TARGET 2 Odds Odds Ratio Ratio (95% CI) p-value (1.10,2.12) (95% CI) p-value (1.10,2.12) (1.05,2.01) (1.05,2.01) (1.18,1.88) (1.18,1.88) Key Key Secondary Secondary IBS Bloating Weekly IBS Bloating Weekly TARGET TARGET 1 TARGET TARGET (1.16,2.27) (1.16,2.27) (1.08,2.06) (1.08,2.06) (1.23,1.96) (1.23,1.96) Other Other Secondary Secondary SGA-IBS Daily SGA-IBS Daily IBS Bloating IBS Bloating Daily Daily IBS Ab Pain IBS Ab Pain Daily Daily TARGET TARGET 1 TARGET TARGET 2 TARGET TARGET 1 TARGET TARGET 2 TARGET TARGET 1 TARGET TARGET (1.26,2.47) (1.26,2.47) (1.13,2.24) (1.28,2.04) (1.13,2.24) (1.28,2.04) (1.01,1.97) (1.01,1.97) (1.26,2.44) (1.26,2.44) (1.21,1.92) (1.21,1.92) (1.05,2.02) (1.05,2.02) (1.05,2.03) (1.05,2.03) (1.13,1.78) (1.13,1.78) < < FDA FDA Proposed Proposed Ab Pain Stool Ab Pain & Stool Daily (FDA) Daily (FDA) Ab Pain Daily Ab Pain Daily (FDA) (FDA) Stool Consist. Stool Consist. Daily (FDA) Daily (FDA) TARGET TARGET 1 TARGET TARGET 2 TARGET TARGET 1 TARGET TARGET 2 TARGET TARGET 1 TARGET TARGET (1.02,1.92) (1.02,1.92) (1.12,2.13) (1.12,2.13) (1.17,1.84) (1.17,1.84) (1.08,2.03) (1.08,2.03) (1.06,2.00) (1.17,1.83) (1.06,2.00) (1.17,1.83) (1.25,2.59) (1.25,2.59) (1.12,2.21) (1.12,2.21) (1.31,2.14) (1.31,2.14) < < Pimentel, et al NEJM, Odds Ratio and 95% CI Odds Ratio and 95% CI Favors Placebo Favors Rifaximin Favors Placebo Favors Rifaximin

19 TARGET 1 and 2 Durable IBS Response Primary Efficacy Outcome SGA-IBS Weekly Study TARGET 1 TARGET 2 Odds Ratio (95% CI) (1.00, 1.82) (1.13, 2.03) (1.17, 1.77) p-value Key Secondary IBS Bloating Weekly TARGET 1 TARGET (0.95, 1.73) (1.16, 2.09) (1.15, 1.75) Other Secondary SGA-IBS Daily IBS Bloating Daily IBS Ab Pain Daily TARGET 1 TARGET 2 TARGET 1 TARGET 2 TARGET 1 TARGET (1.18, 2.18) (1.09, 1.99) (1.20, 1.83) (1.10, 2.04) (1.24, 2.25) (1.24, 1.89) (1.00, 1.83) (1.01, 1.81) (1.06, 1.61) < FDA Proposed Ab Pain & Stool Daily (FDA) Ab Pain Daily (FDA) Stool Consist. Daily (FDA) TARGET 1 TARGET 2 TARGET 1 TARGET 2 TARGET 1 TARGET (1.01, 1.83) (1.08, 1.92) (1.14, 1.72) (0.98, 1.75) (1.03, 1.83) (1.09, 1.64) (1.24, 2.33) (1.09, 2.00) (1.27, 1.97) < Odds Ratio and 95% CI Pimentel, et al NEJM, 2011 Favors Placebo Favors Rifaximin

20 Effect of Rifaximin (10 years later) Increasing rifaximin use 40% reduction in D-IBS Oh SJ, et al DDW 2017

21 Drugs for Bugs -Proteins -Gases -Toxins -Adhesins -Flagellae -Sterols -Obesity -IBS -IBD -Constipation -Others Block pathway for these human harmful byproducts Pros Simple Very promising (e.g. C diff) Cons Complications FDA hurdles What is normal feces?

22 Non-Antibiotic Drugs Block adhesion (Prevent retention) Dozens of products that could affect host

23 Statins and Methane Lovastatin was later discovered from Aspergillus spp Akiro Endo (1971) discovered mevastatin which is a chemical produced by certain fungi to defend against other organisms Mevastatin was toxic to humans

24 How Lovastatin Would Help Hydrogen (H 2 ) Lovastatin Syntroph F420 Methane (CH 4 ) M. smithii F420 is the key enzyme in path that makes methane in M. smithii

25 Lovastatin Lactone and F420 Enzyme Muskal SM, et al. F ;5:606.

26 Lovastatin Timed Release Phase 2 Trial Study 1 Study 2 SYN mg (19) SYN mg (54) CH 4 >10 ppm SYN mg (22) Placebo (22) Subjects who successfully completed Study 1 were transferred to active drug at Day 29 Screen Day Gottlieb K, et al. DDW Lactulose breath test (LBT)

27 Breath Methane AUC at Week 12 (ppm*h) Methane Correlates with Improved Symptoms on Lovastatin p = Gottlieb K, et al. DDW Weekly No. Complete Spontaneous Bowel Movements (CSBMs)

28 Clinical Responders by Month Month Month Month Month Dose Month 1 Dose Months 2,3 Gottlieb K, et al. DDW 2016.

29 No. Subjects Using Rescue Medication % Subjects Using Rescue Medication in Study Lovastatin Timed Release Daily use of RLax (bisacodyl; 5 mg) Placebo SYN mg SYN mg in Study Study Day 100% % Subjects using RLax (bisacodyl; 5 mg) 90% 80% 70% 60% 50% 40% 30% 20% 10% % in Study % *p=0.013 vs Placebo p=0.03 vs Placebo Fisher s exact test 21.1% Placebo SYN mg SYN mg Gottlieb K, et al. DDW 2016.

30 Company Product Indication Stool Open biome Stool CDI RBX2660 Rebiotix Purified stool bacteria CDI, IBD MET-1 Nubiyota 33 bacteria probiotic CDI SER-109 Seres Spores to re-establish flora CDI SER-287 Seres Spores IBD VE-202 Vedanta Clostridium that restores IBD CBM-588 Osel Clostridium butyricum CDI, IBD L plantarum Optibiotix L plantarum Obesity CNDO-201 Fortress Trichuris suis Crohns Blautix 4D pharma Bacterial blend IBS Thetanix - Anti-inflam protein from bacteroides IBD AG-014 Intrexon Genetic modified lactobac secreting anti-inflam chemicals IBD SHP-01 Symbiotic Lysin antimicrobial enzyme CDI VT-301 ViThera Elafin producing lactobacillus IBD SGM nd Genome Molecule inhibits host microbe interaction IBD SYN-004 Synthetic Biologics Β-lactamase CDI prevent SYN-010 Synthetic Biologics Block methane production Constip Rifaximin Salix Gut specific microbial modulator D-IBS Early phase Failing Phase II+ Approved

31 Conclusion 1. There are emerging therapeutics directed at the gut microbiome to treat human disease 2. Most are using bugs as drugs 3. Future therapies will include drugs for bugs 4. There needs to be an increased tolerance load for investment in this area of work

APDW 2016 Poster No. a90312

APDW 2016 Poster No. a90312 APDW 2016 Poster No. a90312 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients with IBS-C Results of a multi-center,

More information

Gut Microbes: Systemic Disease. Mark Pimentel, MD. Cedars-Sinai Medical Center. Mark Pimentel, MD, FACG

Gut Microbes: Systemic Disease. Mark Pimentel, MD. Cedars-Sinai Medical Center. Mark Pimentel, MD, FACG Gut Microbes: Role in Health, IBS, GI and Systemic Disease Mark Pimentel, MD Director, GI Motility Program Cedars-Sinai Medical Center 1 Lacks cellulase cannot breakdown cellulose Depends completely on

More information

ROLE OF THE GUT BACTERIA

ROLE OF THE GUT BACTERIA ROLE OF THE GUT BACTERIA Our Good Bacteria In a perfect world, we would all have a proper ratio of good bacteria And what could this proper ratio do for us? The knowledge of the connections between our

More information

New Developments in Irritable Bowel Syndrome

New Developments in Irritable Bowel Syndrome New Developments in Irritable Bowel Syndrome Mark Pimentel, MD, FRCP(C) Director, GI Motility Program Cedars-Sinai Medical Center IBS Forks in the Road Not all decisions in how to handle IBS made things

More information

William Chey, MD University of Michigan Ann Arbor, MI

William Chey, MD University of Michigan Ann Arbor, MI Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA William Chey, MD University of Michigan Ann Arbor, MI Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Accredited by Jointly

More information

Understanding probiotics and health

Understanding probiotics and health Understanding probiotics and health Gemma Laws MSc Student Microbiology and Immunology Department The gut microbiota The name given to the total microbial population living in our intestine Bacteria, fungi,

More information

The Potential For Microbiome Modification In Critical Illness. Deborah Cook

The Potential For Microbiome Modification In Critical Illness. Deborah Cook The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to

More information

SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT

SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

More information

The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH

The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH The Epidemiology of Clostridium difficile DANIEL SAMAN, DRPH, MPH RESEARCH SCIENTIST ESSENTIA INSTITUTE OF RURAL HEALTH Some history first Clostridium difficile, a spore-forming gram-positive (i.e., thick

More information

Clinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut

Clinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,

More information

What Are Probiotics? PROBIOTICS

What Are Probiotics? PROBIOTICS PROBIOTICS What Are Probiotics? Probiotics are living, microscopic (very small) organisms that can help your gut health. Most often, probiotics are bacteria, but they may also be other organisms, such

More information

Microbiome in You: Optimizing Gut Bacteria for Better IBD Management

Microbiome in You: Optimizing Gut Bacteria for Better IBD Management Microbiome in You: Optimizing Gut Bacteria for Better IBD Management KT Park, M.D., M.S. Assistant Professor Co-Director, Stanford Children s Inflammatory Bowel Disease Center Stanford University School

More information

Disarming C. diff bacteria without destroying healthy gut flora

Disarming C. diff bacteria without destroying healthy gut flora Disarming C. diff bacteria without destroying healthy gut flora Stanford University School of Medicine scientists successfully defeated a dangerous intestinal pathogen, Clostridium difficile, with a drug

More information

The Human Microbiome Christine Rodriguez, Ph.D. Harvard Outreach 2012

The Human Microbiome Christine Rodriguez, Ph.D. Harvard Outreach 2012 The Human Microbiome Christine Rodriguez, Ph.D. Harvard Outreach 2012 Microbes are all over us Page 1 of 22 There are millions of microbes per square inch on your body Thousands of different species on

More information

Microbiome GI Disorders

Microbiome GI Disorders Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things

More information

Hompes Method. Practitioner Training Level II. Lesson Seven Part A DRG Pathogen Plus Interpretation

Hompes Method. Practitioner Training Level II. Lesson Seven Part A DRG Pathogen Plus Interpretation Hompes Method Practitioner Training Level II Lesson Seven Part A DRG Pathogen Plus Interpretation Health for the People Ltd not for reuse without expressed permission Hompes Method is a trading name of

More information

Stool Testing for the Microbiome - Ready for Primetime?

Stool Testing for the Microbiome - Ready for Primetime? Stool Testing for the Microbiome - Ready for Primetime? Gillian M. Barlow, PhD Project Scientist, Medically Associated Science and Technology (MAST) Program Cedars-Sinai Medical Center Take Charge of

More information

Corporate Medical Policy Fecal Microbiota Transplantation

Corporate Medical Policy Fecal Microbiota Transplantation Corporate Medical Policy Fecal Microbiota Transplantation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Fecal_microbiota_transplantation 7/2014 11/2017 11/2018 11/2017 Description

More information

The effect of probiotics on animal health: a focus on host s natural intestinal defenses

The effect of probiotics on animal health: a focus on host s natural intestinal defenses The effect of probiotics on animal health: a focus on host s natural intestinal defenses Guillaume Tabouret Animal Health Dept. Joint Unit 1225 Host Pathogens Interactions History of probiotics and definition

More information

Corporate Overview. August Leading the Microbiome Revolution

Corporate Overview. August Leading the Microbiome Revolution Corporate Overview August 2018 Leading the Microbiome Revolution Forward looking statements Some of the statements in this presentation constitute forward looking statements under the Private Securities

More information

Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report

Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report Qiurong Li Institute of General Surgery, Jinling Hospital Nanjing Univeristy Gut Microbiota 100 trillion cells 10-fold of

More information

The role of gut microbiome in IBS

The role of gut microbiome in IBS The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard

More information

Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations

Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fecal Microbiota Transplantation in C. diff. colitis Benefits and Limitations Gerhard Rogler,

More information

Dysbiosis & Inflammation

Dysbiosis & Inflammation MASTERING THE MICROBIOME: Dysbiosis & Inflammation 2017 Tom Fabian, PhD It is reasonable to propose that the composition of the microbiome and its activities are involved in most, if not all, of the biological

More information

Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile

Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile Infection: Application of a Novel Diagnostic for Dysbiosis Courtney Jones, BS Rebiotix Inc. Roseville, MN USA

More information

Probiotics: Their Role in Medicine Today. Objectives. Probiotics: What Are They? 11/3/2017

Probiotics: Their Role in Medicine Today. Objectives. Probiotics: What Are They? 11/3/2017 Probiotics: Their Role in Medicine Today Viki Barr Pharm.D., BCPS AQ ID Assistant Professor, Pharmacy Practice Rosalind Franklin University of Medicine and Science Clinical Pharmacist, Infectious Diseases

More information

Increasing barrier function with multispecies probiotics

Increasing barrier function with multispecies probiotics Increasing barrier function with multispecies probiotics Elsbeth Pekelharing, MSc Science Liaison We strive for the most effective microbiome management solutions with our evidence-based & indication-specific

More information

HOW THE MICROBIOME AFFECTS OUR HEALTH

HOW THE MICROBIOME AFFECTS OUR HEALTH HOW THE MICROBIOME AFFECTS OUR HEALTH THE INTESTINAL BARRIER AND INTESTINAL PERMEABILITY Intestinal Barrier: a functional body Defense from translocation of dietary antigens, bacteria or bacterial endotoxins

More information

4/17/2019 DISCLOSURES OBJECTIVES GI MICROBIOME & HEALTH: A REVIEW. Nancy C. Kois, MD, FCAP Contemporary Pathology Services. There are no disclosures

4/17/2019 DISCLOSURES OBJECTIVES GI MICROBIOME & HEALTH: A REVIEW. Nancy C. Kois, MD, FCAP Contemporary Pathology Services. There are no disclosures GI MICROBIOME & HEALTH: A REVIEW Nancy C. Kois, MD, FCAP Contemporary Pathology Services DISCLOSURES There are no disclosures OBJECTIVES Definitions: GI microbiota, GI microbiome, probiotic, prebiotic

More information

AUTOIMMUNITY AND THE GUT

AUTOIMMUNITY AND THE GUT AUTOIMMUNITY AND THE GUT Autoimmunity The Past The rationale - All about a malfunctioning immune system The immune system is overactive to the point of attacking the body Avoid anything that stimulates

More information

What are probiotics? How do probiotics benefit health?

What are probiotics? How do probiotics benefit health? The culture club So, you re clean eating, gluten free, fasting, eating avocados like their going out of fashion, chugging down green juices with the latest wonder powders and using coconut oil to cook

More information

Microbiome. A new dimension in Medicine. Israel De Alba, MD MPH. Clinical Professor

Microbiome. A new dimension in Medicine. Israel De Alba, MD MPH. Clinical Professor Microbiome A new dimension in Medicine Israel De Alba, MD MPH Clinical Professor AIM To look at ordinary things from a different perspective.to jump start curiosity Reason to have lunch We know so much

More information

FECAL TRANSPLANTATION

FECAL TRANSPLANTATION FECAL TRANSPLANTATION From Theory to Practice in Ridge Meadows Edward Auersperg 13 January 2016 The Human Genome How many different chromosomes do humans have? 46 chromosomes 23 pairs The Human Genome

More information

Faecalibacterium prausnitzii

Faecalibacterium prausnitzii Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients PNAS 105(43): 16731-16736, 2008. Speaker: Ming-Cheng Chen Advisor:

More information

1. BACKGROUND. Lovastatin β-hydroxyacid No effect on methane production Inhibits cholesterol synthesis

1. BACKGROUND. Lovastatin β-hydroxyacid No effect on methane production Inhibits cholesterol synthesis 1. BACKGRUND Methane production by the archeon Methanobrevibacter smithii (M. smithii) is a ubiquitous process in the intestine, disposing of hydrogen and other by-products formed during carbohydrate digestion

More information

Bacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: Rare. Rare. Positive. Brown. Negative *NG. Negative

Bacteriology. Mycology. Patient: SAMPLE PATIENT DOB: Sex: MRN: Rare. Rare. Positive. Brown. Negative *NG. Negative Patient: SAMPLE PATIENT DOB: Sex: MRN: 3.2 0.9-26.8 U/g 1.2 0.2-3.3 mg/g 2.2 1.3-8.6 micromol/g 1.1 1.3-23.7 mg/g 1.1 0.2-3.5 mg/g Rare 1.0 0.2-8.8 mg/g Rare 4.4 2.6-32.4 mg/g 64.6 >= 13.6 micromol/g Bacteriology

More information

SIBO

SIBO SIBO What is it? Small Intestinal Bowel Overgrowth A chronic bacterial infection of the small intestine Caused by bad bacteria such as E Coli and Clostridium migrating to the small intestine There is not

More information

Ever wonder what s really happening on the inside?

Ever wonder what s really happening on the inside? For Practitioners Ever wonder what s really happening on the inside? Are your patients suffering from diarrhea, constipation, bloating, gas or indigestion? Rocky Mountain Analytical is now offering Gut-Well

More information

E. coli Nissle 1917 A Unique Medical Probiotic and it s Clinical Applications. Sudesh Samuel Scientific Director Amber Laboratories

E. coli Nissle 1917 A Unique Medical Probiotic and it s Clinical Applications. Sudesh Samuel Scientific Director Amber Laboratories E. coli Nissle 1917 A Unique Medical Probiotic and it s Clinical Applications Sudesh Samuel Scientific Director Amber Laboratories Content E. coli s background Gut Microbiome Pathogenic E. coli Probiotic

More information

Laboratory report. Test: Leaky gut test. Sample material: stool. John Doe Main St 1 Anytown

Laboratory report. Test: Leaky gut test. Sample material: stool. John Doe Main St 1 Anytown 1 / 5 Verisana LAB John Doe Main St 1 Anytown Surname, First name Doe, John DOB 02/13/1980 Sex male Laboratory # 20020181 Date collected 01/25/2018 Date received 02/01/2018 Report date 02/13/2018 Laboratory

More information

2/3/2011. Adhesion of Bifidobacterium lactis HN019 to human intestinal

2/3/2011. Adhesion of Bifidobacterium lactis HN019 to human intestinal PROBIOTICS LEARNING THE WHY AND WHEN PROBIOTICS DEFINITION live micro-organisms organisms that are beneficial to the host organism WHO: Live organisms which, when administered in adequate amounts, confer

More information

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate

Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Clostridium Difficile Infection: Applying New Treatment Guidelines and Strategies to Reduce Recurrence Rate Objectives Summarize the changing epidemiology and demographics of patients at risk for Clostridium

More information

more intense treatments are needed to get rid of the infection.

more intense treatments are needed to get rid of the infection. What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting

More information

SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017

SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation

More information

All POOPed out: fecal microbiota transplant in C. difficile

All POOPed out: fecal microbiota transplant in C. difficile All POOPed out: fecal microbiota transplant in C. difficile SUSAN M. KELLIE, MD, MPH PROFESSOR OF INTERNAL MEDICINE DIVISION OF INFECTIOUS DISEASES UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE HOSPITAL

More information

Module Four: The GI System Module Five: The Gut Microbiome. The GI System. LLiana Shanti, CN

Module Four: The GI System Module Five: The Gut Microbiome. The GI System. LLiana Shanti, CN Module Four: The GI System Module Five: The Gut Microbiome The GI System LLiana Shanti, CN www.healthmasteryinstitute.com Review Review Review The Gut Hippocrates has been quoted as saying death sits in

More information

Pennington Feb 19, 2015

Pennington Feb 19, 2015 Trust your gut Pennington Feb 19, 2015 Crohn s Disease -an autoimmune disorder that causes inflammation of the intestinal tract along with unpredictable, often incapacitating episodes of abdominal pain

More information

Formulations and Availability 900 BILLION 5,319 HIGH POTENCY PROBIOTIC PEDIATRIC ADULT GERIATRIC PROVEN BY RESEARCH. HIGH-POTENCY. NO SHORTCUTS.

Formulations and Availability 900 BILLION 5,319 HIGH POTENCY PROBIOTIC PEDIATRIC ADULT GERIATRIC PROVEN BY RESEARCH. HIGH-POTENCY. NO SHORTCUTS. Formulations and Availability S TU D I E S PE R D I S E A S E 39 LIVER Liver Disease, Cirrhosis, Liver Failure, Hepatic Encephalopathy S TU D I E S PE R AG E G RO U P Visbiome Regular Product Code: 693-0412-01

More information

The good, the bad and the ugly. Our microbiome and it s effect on health and disease.

The good, the bad and the ugly. Our microbiome and it s effect on health and disease. The good, the bad and the ugly Our microbiome and it s effect on health and disease. Objectives Discuss C difficile infection including treatment options Explain process of Fecal MicrobiotaTransplantation

More information

Functional Nutrition Approaches to Gut Health 20 CPEU Module accredited by Nutrition Mission

Functional Nutrition Approaches to Gut Health 20 CPEU Module accredited by Nutrition Mission Topics Covered 1. Good Health Starts in the Gut 2. Microbiome Part 1 3. Microbiome Part 2 4. What Can Go Wrong 5. FODMAP Intolerance 6. GERD 7. Celiac Disease 8. Non-Celiac Gluten Sensitivity 9. Intestinal

More information

Regulatory challenges in the drug-food continuum. Yolanda Sanz IMI Stakeholder Forum Microbiome Brussels, Belgium

Regulatory challenges in the drug-food continuum. Yolanda Sanz IMI Stakeholder Forum Microbiome Brussels, Belgium Regulatory challenges in the drug-food continuum Yolanda Sanz 19.10.2017 IMI Stakeholder Forum Microbiome Brussels, Belgium Outline Regulation of health claims on foods EU No 1924/2006 Reconciling science

More information

Treatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department

Treatment Update on Fecal Microbiota Transplantation. Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Treatment Update on Fecal Microbiota Transplantation Arnab Ray, MD Ochsner Clinic Foundation Gastroenterology Department Disclosure I serve as a paid medical monitor for Rebiotix Objectives The scope of

More information

Current Concepts in VAP: Stress Ulcer Prophylaxis & Probiotics. Deborah Cook

Current Concepts in VAP: Stress Ulcer Prophylaxis & Probiotics. Deborah Cook Current Concepts in VAP: Stress Ulcer Prophylaxis & Probiotics Deborah Cook Objectives VAP The Old: Gastropulmonary route of infection The New: Microbiome modification Role of acid suppression Influence

More information

Manipulating the gut microbiome

Manipulating the gut microbiome Manipulating the gut microbiome William DePaolo, PhD Associate Professor Medicine Director Center for Microbiome Sciences & Therapeutics University of Washington Microbiota The actual bugs that reside

More information

!Microbiology Profile, stool

!Microbiology Profile, stool LAB #: F000000-0000-0 PATIENT: Sample Patient ID: P12345 SEX: Female AGE: 37 CLIENT #: 12345 DOCTOR: Doctor's Data, Inc. 3755 Illinois Ave. St. Charles, IL 60174!Microbiology Profile, stool BACTERIOLOGY

More information

When To Do Fecal Microbiota Transplant (FMT) For C. difficile

When To Do Fecal Microbiota Transplant (FMT) For C. difficile When To Do Fecal Microbiota Transplant (FMT) For C. difficile Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College

More information

Fecal Microbial Transplant Effect on Clinical Outcomes and Fecal Microbiome in Active Crohn's Disease

Fecal Microbial Transplant Effect on Clinical Outcomes and Fecal Microbiome in Active Crohn's Disease Fecal Microbial Transplant Effect on Clinical Outcomes and Fecal Microbiome in Active Crohn's Disease March 2015 - Volume 21 - Issue 3 - p 556 563 doi: 10.1097/MIB.0000000000000307 Original Clinical Articles

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Fecal Analysis in the Diagnosis of Intestinal Dysbiosis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: fecal_analysis_for_intestinal_dysbiosis 5/2001 5/2018

More information

Diverticular Disease: Looking beyond fiber

Diverticular Disease: Looking beyond fiber Binghamton University The Open Repository @ Binghamton (The ORB) Health & Wellness Studies Faculty Scholarship Decker School of Nursing Fall 10-28-2015 Diverticular Disease: Looking beyond fiber Lina Begdache

More information

NYSE MKT: SYN. FBR & Co. 2 nd Annual Healthcare Conference

NYSE MKT: SYN. FBR & Co. 2 nd Annual Healthcare Conference NYSE MKT: SYN FBR & Co. 2 nd Annual Healthcare Conference Boston, MA September 9, 2015 Forward-Looking Statements This presentation includes forward-looking statements on Synthetic Biologics current expectations

More information

12/1/2017. Disclosures. Objectives. The Microbiome Defined

12/1/2017. Disclosures. Objectives. The Microbiome Defined Can Critical Illness and the Microbiome Play Nice Together? SCOTT BOLESTA, PHARMD, BCPS, FCCM ASSOCIATE PROFESSOR OF PHARMACY PRACTICE, WILKES UNIVERSITY VISITING INVESTIGATOR, GEISINGER HEALTH SYSTEM

More information

Poultry The unique probiotic

Poultry The unique probiotic Poultry The unique probiotic Probiotics Probiotics have been defined as live microbial feed supplements which beneficially affect the host animal by improving its intestinal microbial balance. Achieving

More information

ESPEN Congress Vienna Networking with your microbiota Specific evidence-based indications. H. Lochs (Germany)

ESPEN Congress Vienna Networking with your microbiota Specific evidence-based indications. H. Lochs (Germany) ESPEN Congress Vienna 2009 Networking with your microbiota Specific evidence-based indications H. Lochs (Germany) Probiotics Evidence based indications H. Lochs Medizinische Klinik mit Schwerpunkt Gastroenterologie,

More information

10/4/2014. The Microbiome vs. the Gastroenterologist. Human Microbiome. Microbiome and Host Physiology: A Delicate Balance

10/4/2014. The Microbiome vs. the Gastroenterologist. Human Microbiome. Microbiome and Host Physiology: A Delicate Balance The Microbiome vs. the Gastroenterologist John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Human Microbiome Mouth Finlay BB. Scientific American 2010;302:56-63 Microbiome

More information

C. difficile: When to Do Fecal Microbiota Transplant (FMT)

C. difficile: When to Do Fecal Microbiota Transplant (FMT) C. difficile: When to Do Fecal Microbiota Transplant (FMT) Lawrence J. Brandt, MD, MACG Emeritus Chief, Gastroenterology Montefiore Medical Center Professor of Medicine and Surgery Albert Einstein College

More information

Module Outline. 1. Microbiome overview: getting a sense of the microbiome, research, what we know

Module Outline. 1. Microbiome overview: getting a sense of the microbiome, research, what we know Module Outline 1. Microbiome overview: getting a sense of the microbiome, research, what we know 2. Bacteria: features, functions, communities & taxonomy 3. Other microbes: archaea, fungi, viruses, parasites

More information

The Bi-Phasic SIBO Protocol Module 1 Diagnosing SIBO

The Bi-Phasic SIBO Protocol Module 1 Diagnosing SIBO Dr Nirala Jacobi, BHSc, ND Author, SIBO Bi-Phasic Treatment Protocol and the SIBO Bi-Phasic Diet Medical Director, SIBOTest.com and host of TheSIBODoctor.com The Bi-Phasic SIBO Protocol Module 1 Diagnosing

More information

Nicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia. Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA

Nicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia. Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Lin Chang, MD David Geffen School of Medicine at UCLA Los Angeles, CA Mark Pimentel, MD Cedars-Sinai Medical Center Los Angeles, CA Nicholas J. Talley, MD University of Newcastle Callaghan, NSW Australia

More information

Gut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI

Gut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI Gut Microbiota and IBD Vahedi. H M.D Associate Professor of Medicine DDRI 1393.3.1 2 GUT MICROBIOTA 100 Trillion Microbes - 10 times more than cells in our body Collective weight of about 1kg in human

More information

Exosomes as a. Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE

Exosomes as a. Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE Exosomes as a Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE Endocrine Nurse Practitioner Institute for Hormonal Balance Orlando, FL Medical Director Ward-Murray

More information

Irritable Bowel Syndrome Causes and Treatments

Irritable Bowel Syndrome Causes and Treatments Irritable Bowel Syndrome Causes and Treatments Oh heck. Gas, bloating, alternating constipation and diarrhea, food cravings and abdominal pain. Your symptoms may be significant and cause you embarrassment

More information

The role of the microbiome in type 2 diabetes

The role of the microbiome in type 2 diabetes The role of the microbiome in type 2 diabetes Expert Forum on diabetes: Genetics, nutrition and the future of diabetes management 10 October 2017 Luc Sterkman, MD CEO Caelus Health Bugs in daily life Good

More information

Patient presentation

Patient presentation Update: Clostridium difficile Colitis David H. Kerman, MD Assistant Professor of Clinical Medicine Director, Fellowship Program Division of Gastroenterology University of Miami Miller School of Medicine

More information

Research Update: Looking for the Answers

Research Update: Looking for the Answers Research Update: Looking for the Answers Ted Denson, M.D. Schubert-Martin Inflammatory Bowel Disease Center Research Support: NIH/NIDDK, CCFA, BMRP Figure 2 Approach to Improve Outcomes for our IBD Patients

More information

2/13/2018. What s bugging you? Relevance of the Human Microbiome in Health and Disease Heidi H. Kong, MD, MHSc, FAAD Dermatology Branch

2/13/2018. What s bugging you? Relevance of the Human Microbiome in Health and Disease Heidi H. Kong, MD, MHSc, FAAD Dermatology Branch What s bugging you? Relevance of the Human Microbiome in Health and Disease Heidi H. Kong, MD, MHSc, FAAD Dermatology Branch DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Heidi H Kong, MD, MHSc, FAAD U017:

More information

Clinical Policy Bulletin: Fecal Bacteriotherapy

Clinical Policy Bulletin: Fecal Bacteriotherapy Clinical Policy Bulletin: Fecal Bacteriotherapy Number: 0844 Policy Aetna considers fecal bacteriotherapy medically necessary for persons with Clostridium difficile infection, with infection confirmed

More information

MegaSporeBiotics Probiotics. Linda Wilbert - Stewart, FDN, HHP, HC 1/28/

MegaSporeBiotics Probiotics.   Linda Wilbert - Stewart, FDN, HHP, HC 1/28/ MegaSporeBiotics Probiotics www.exclusivelyholistic.com Linda Wilbert - Stewart, FDN, HHP, HC 1/28/2015 111 MegaSporeBiotic is the first, all spore, carotenoid rich, probiotic consortium formulation on

More information

general meeting 1 20 October 2016

general meeting 1 20 October 2016 general meeting 1 20 October 2016 introductions today s topics the human microbiome about the study the human microbiome the human microbiome human microbiota: the microorganisms that live within and on

More information

SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT

SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

More information

T H E B E T T E R H E A L T H N E W S

T H E B E T T E R H E A L T H N E W S Dr. Paul G. Varnas & WholeHealthAmerica.com present V O L U M E 1 3, I S S U E 4 T H E B E T T E R H E A L T H N E W S A P R I L, 2 0 1 6 M O R E P R O B L E M S W I T H P R O T O N P U M P I N H I B I

More information

Gut bugs and health. Patrick Bateson

Gut bugs and health. Patrick Bateson Gut bugs and health Patrick Bateson Characteristic odour of kin group is produced by inherited bacterial flora degrading fats secreted by anal glands An increasing number of people in developed countries

More information

UNDERSTANDING PROBIOTIC SUPPLEMENTS

UNDERSTANDING PROBIOTIC SUPPLEMENTS UNDERSTANDING PROBIOTIC SUPPLEMENTS Probiotics Health Canada Definition: Probiotics are considered to be live microorganisms which, when administered in adequate amounts, confer a health benefit on the

More information

SIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello. Microbiota e IBS.

SIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello. Microbiota e IBS. SIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello Microbiota e IBS Cesare Cremon Policlinico S. Orsola Malpighi Azienda Ospedaliero - Universitaria di

More information

The vital role of the microbiome in human health

The vital role of the microbiome in human health The vital role of the microbiome in human health abandoning hygiene is not the way to a healthy microbiome Colin Hill APC Microbiome Institute University College Cork @colinhillucc Mixed messages? We live

More information

UNDERSTANDING PROBIOTIC SUPPLEMENTS

UNDERSTANDING PROBIOTIC SUPPLEMENTS Slide 1 UNDERSTANDING PROBIOTIC SUPPLEMENTS Slide 2 Probiotics Health Canada Definition: Probiotics are considered to be live microorganisms which, when administered in adequate amounts, confer a health

More information

11/13/18. MICROBIOME AND THE BRAIN: How your gut impacts wellbeing. Approach. Lessons from Venice. Session One. Sue Langley

11/13/18. MICROBIOME AND THE BRAIN: How your gut impacts wellbeing. Approach. Lessons from Venice. Session One. Sue Langley MICROBIOME AND THE BRAIN: How your gut impacts wellbeing Session One Sue Langley 2018 2017 Langley Group IP Trust Approach Lessons from Venice 1 Lessons from Venice Agenda 2. Implications and research

More information

Small Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results

Small Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results Small Intestinal Bacterial Overgrowth-Symptoms, Diagnosis, and Treatment of Patients with Positive and Negative Results Martin Carr, M.D. March 3, 2018 Good evening everyone, this is Martin Carr, and I

More information

Pigs The unique probiotic

Pigs The unique probiotic Pigs The unique probiotic PROBIOTICS Probiotics have been defined as live microbial feed supplements which beneficially affect the host animal by improving its intestinal microbial balance. Achieving a

More information

Spectrum of Diverticular Disease. Outline

Spectrum of Diverticular Disease. Outline Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives

More information

1. Nutrient and calorie extraction from our foods which determines how well nourished we are - and how well we can regulate our weight

1. Nutrient and calorie extraction from our foods which determines how well nourished we are - and how well we can regulate our weight The digestive system (gut) is a tube that begins at the mouth at the top and ends at the anus. Along the way one encounters the stomach, small intestines, and large intestines. Each of these regions has

More information

CULINARY HERBS AND SPICES

CULINARY HERBS AND SPICES CULINARY HERBS AND SPICES Using Culinary Herbs and Spices Flavour and texture are a huge issue when it comes to introducing new foods to a client Herb and spices can help make a new food seem like an old

More information

Myalgic encephalomyelitis: A highly prevalent debilitating disease

Myalgic encephalomyelitis: A highly prevalent debilitating disease Myalgic encephalomyelitis: A highly prevalent debilitating disease Persistent, debilitating fatigue associated with numerous physical and neurocognitive symptoms Disease severity can range from moderate

More information

What GI Physicians Need to Know About Probiotics

What GI Physicians Need to Know About Probiotics Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/gi-insights/what-gi-physicians-need-to-know-about-probiotics/3844/

More information

HMP is lead by NIH but is an International Consortium.

HMP is lead by NIH but is an International Consortium. Human Microbiome The Human Microbiome Project was one of the spin offs of the Human Genome Project. The HMP project started in 2007 with the overall goal of Characterizing the Human Microbiome and determine

More information

The science behind probiotics Colin Hill, APC Microbiome Institute University College Cork Ireland

The science behind probiotics Colin Hill, APC Microbiome Institute University College Cork Ireland The science behind probiotics Colin Hill, APC Microbiome Institute University College Cork Ireland Illustration Charis Tsevis Probiotics live microorganisms that, when administered in adequate amounts,

More information

PROBIOTICS. what they are and what they can do for you. A patient s guide from your doctor and

PROBIOTICS. what they are and what they can do for you. A patient s guide from your doctor and PROBIOTICS what they are and what they can do for you A patient s guide from your doctor and Probiotics Products containing probiotics have flooded the market in recent years. As more people seek natural

More information

Probiotics for Primary Prevention of Clostridium difficile Infection

Probiotics for Primary Prevention of Clostridium difficile Infection Probiotics for Primary Prevention of Clostridium difficile Infection Objectives Review risk factors for Clostridium difficile infection (CDI) Describe guideline recommendations for CDI prevention Discuss

More information

Is FMT the answer? Challenging Cases in CDI. Ted Steiner, M.D. April 1, 2016

Is FMT the answer? Challenging Cases in CDI. Ted Steiner, M.D. April 1, 2016 Is FMT the answer? Challenging Cases in CDI Ted Steiner, M.D. April 1, 2016 CONFLICT OF INTEREST DISCLOSURE SLIDE In the past 2 years I have been an employee of: In the past 2 years I have been a consultant

More information

Hompes Method. Practitioner Training Level II. Lesson Five (a) Bad Bugs - Bacteria

Hompes Method. Practitioner Training Level II. Lesson Five (a) Bad Bugs - Bacteria Hompes Method Practitioner Training Level II Lesson Five (a) Bad Bugs - Bacteria Health for the People Ltd not for reuse without expressed permission Hompes Method is a trading name of Health For The People

More information

DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit

DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which

More information